Gelfand JM, Shin DB, Duffin KC, et al. - In this randomized placebo-controlled trial, researchers analyzed the impact of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis, a chronic immune-mediated disease. Following a 12-week randomized, placebo-controlled, double-blind treatment period, individuals with moderate-to-severe psoriasis received secukinumab for 40 weeks. Small increases in total cholesterol, low-density lipoprotein, and low-density lipoprotein particles, but no improvements in markers of inflammation, adiposity, insulin resistance, or diabetes predictors, were recorded with secukinumab treatment compared with placebo. With secukinumab treatment, no significant changes in aortic inflammation or markers of advanced lipoprotein characterization, adiposity, or insulin resistance were identified relative to baseline. After 52 weeks of treatment, secukinumab demonstrated a neutral effect on aortic vascular inflammation and cardiometabolic disease biomarkers.